Pharma companies are striving to convey the true impact of diseases on patients while continuing to empower them.
As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.
As the public’s interest in COVID-19 products continues to wane and the autoimmune medicine Humira settles into life without exclusivity, the anti-cancer agent Keytruda is set to rule the drug marketplace for years to come.
In a less-than-shocking development, the top drugs of the launch class of 2021 were all for preventing or treating everyone’s least favorite virus.
Blockbuster deals are on the rise as drug manufacturers navigate through patent cliffs, pricing pressures, and evolving regulations while M&A activity remains an integral part of the strategic landscape.
Wow, this headline is ironic. I wrote it March 27, 2023. I took the photo March 29, 2023. After successfully ducking the ’vid for three years, the ’vid found me.
Dealing with the seismic effects of the COVID-19 pandemic, the biopharma industry continues to break new ground during a transformative era of product innovation.
Part I: Leaders in healthcare marketing and communications reflect on the push to attract and retain industry talent.
Part II: Leaders in healthcare marketing and communications discuss the looming concerns regarding the healthcare ecosystem.
Part III: Leaders in healthcare marketing and communications explain where technology will have the most impact on the industry.